1. Pink Sheet
  2. >>Compliance

Novartis To Make Its Medical Education Programs Virtual Under DOJ Settlement

 
• By Brenda Sandburg

Two settlements totaling $729m resolve kickback claims related to speaker programs and copay charities; Novartis will limit payments to healthcare professionals for providing medical education under a new corporate integrity agreement.

Washington DC - Department of Justice Building
Novartis to pay $729m to resolve two DOJ complaints

In settling claims it used speaker programs to pay kickbacks to doctors, Novartis Pharmaceuticals Corp. is altering the way it conducts medical education, moving most of its programs into the digital realm.

On 2 July, the company announced it had finalized a $678m settlement with the US Department of Justice to resolve...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.